INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
Back to Newsroom
Mentioned in this Article

INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm

Tuesday, April 20, 2021 12:45 PM
Share this article now
Topic:
Lawsuits

LOS ANGELES, CA / ACCESSWIRE / April 20, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ:IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 2, 2019 and February 1, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 20, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Health Sciences Acquisitions Corporation failed to perform proper due diligence into Immunovant Sciences Ltd. prior to the merger, and ignored or failed to disclose safety problems with IMVT-1401. IMVT-1401 was not as safe as the Company led the market to believe, particularly for the treatment of thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA). These issues would greatly impact the likelihood of IMVT-1401 securing regulatory approval and commercial viability. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Immunovant, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm

The Schall Law Firm
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions